Endo International plc – Ordinary Shares (NASDAQ:ENDP) posted Q3 2017 financial report, wherein it stated that revenue came at $787 million, an 11% drop compared to revenue of $884 million in third-quarter 2016.
Endo International posted net loss of $100 million from continuing operations compared to $191 million in the same period, a year ago. Diluted loss per share came at $0.45 from continuing operations compared to $0.86 in the comparable quarter, a year earlier. Adjusted income came at $204 million from continuing operations versus $226 million recorded in the third-quarter of 2016.
Adjusted diluted EPS was $0.91 from continuing operations as against adjusted diluted EPS of $1.01 from continuing operations in the same quarter of 2016. Paul Campanelli, the CEO and President of Endo, expressed that they continue to implement against their major priorities and achieve robust operating results. The core segments of focus, Branded Specialty Products and Sterile Injectables, are achieving remarkable growth while they continue to lead margin expansion. They look forward to a robust finish to 2017 and they reaffirm the adjusted financial and revenue guidance they issued in August 2017.
Endo reported that total revenue in Q3 2017 dropped by 11% to $787 versus the same period in 2016. The drop was mainly due to previously reported discontinuance of U.S. Generic Pharmaceuticals product, pricing pressure from higher competition mainly impacting the U.S. Generics Base segment, generic competition negatively impacting the performance of Branded Established Products portfolio and the terminating of shipments of OPANA® ER to clients by September 1, 2017. GAAP net loss came at $100 million from continuing operations versus $191 million recorded in the comparable quarter of 2016.
In the last trading session, the stock price of Endo jumped more than 13% to close the day at $6.93. The gains came at a share volume of 12.14 million compared to average share volume of 7.58 million.
This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.financialstrend.com